Fig. 2: AKT rescues cell proliferation and tumor growth of PRMT5-depleted cells.
From: PRMT5-mediated arginine methylation activates AKT kinase to govern tumorigenesis
a MCF7 cells stably expressing myr-AKT1 were infected with shRNA targeting PRMT5 and subjected to IB analysis. Similar results were obtained in n = 3 independent experiments. b, c Cells generated in a were subjected to colony formation and soft agar assays. Representative images are shown in b and relative colony numbers are plotted in c. Data are shown as the mean ± SD of n = 3 or 6 independent experiments. d DLD-1 cells ectopically expressing myr-AKT1 and/or depleting PRMT5 were injected into nude mice. Tumor growth was monitored for the indicated time period. Data are shown as the mean ± SEM for n = 7 mice. e Weight of the tumors. Data are shown as the mean ± SD for n = 7 tumors. f Representative images of IHC staining of Ki-67 in n = 4 xenograft tumors. Scale bar, 100 μm. g Representative images of TUNEL assays in xenograft tumors. Scale bar, 50 μm. h Quantification of TUNEL-positive cells in xenograft tumors. Data are shown as the mean ± SD for n = 4 tumors. Statistical significance was determined by two-tailed Student’s t-test in c, e, h and by two-way ANOVA in d. Uncropped immunoblots and statistical source data are provided in Source Data files.
